MX2023001261A - Polipéptidos de unión a albúmina sérica. - Google Patents

Polipéptidos de unión a albúmina sérica.

Info

Publication number
MX2023001261A
MX2023001261A MX2023001261A MX2023001261A MX2023001261A MX 2023001261 A MX2023001261 A MX 2023001261A MX 2023001261 A MX2023001261 A MX 2023001261A MX 2023001261 A MX2023001261 A MX 2023001261A MX 2023001261 A MX2023001261 A MX 2023001261A
Authority
MX
Mexico
Prior art keywords
polypeptides
serum albumin
binding polypeptides
methods
affimerâ
Prior art date
Application number
MX2023001261A
Other languages
English (en)
Inventor
Emma Jenkins
Estelle Adam
Emma Stanley
Amrik Basran
Matthew P Vincent
Bruno Gomes
Original Assignee
Avacta Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avacta Life Sciences Ltd filed Critical Avacta Life Sciences Ltd
Publication of MX2023001261A publication Critical patent/MX2023001261A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/101—Plasmid DNA for bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento, en algunas modalidades, se proporcionan variantes de polipéptidos de estefina modificadas por ingeniería recombinante (polipéptidos AFFIMER(r)) que se unen a la albúmina sérica humana y prolongan la vida media de los polipéptidos; también se proporcionan aquí, en algunas modalidades, composiciones que contienen los polipéptidos, métodos para usar los polipéptidos y métodos para producir los polipéptidos.
MX2023001261A 2020-07-30 2021-07-30 Polipéptidos de unión a albúmina sérica. MX2023001261A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063059026P 2020-07-30 2020-07-30
PCT/EP2021/071421 WO2022023540A1 (en) 2020-07-30 2021-07-30 Serum albumin-binding polypeptides

Publications (1)

Publication Number Publication Date
MX2023001261A true MX2023001261A (es) 2023-07-19

Family

ID=77543465

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001261A MX2023001261A (es) 2020-07-30 2021-07-30 Polipéptidos de unión a albúmina sérica.

Country Status (12)

Country Link
US (1) US20230272011A1 (es)
EP (1) EP4188957A1 (es)
JP (1) JP2023536584A (es)
KR (1) KR20230070201A (es)
CN (1) CN116419926A (es)
AU (1) AU2021314982A1 (es)
BR (1) BR112023001588A2 (es)
CA (1) CA3187453A1 (es)
IL (1) IL300243A (es)
MX (1) MX2023001261A (es)
TW (1) TW202221030A (es)
WO (1) WO2022023540A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202332694A (zh) * 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之ｐｄ－ｌ１結合多肽
WO2023218243A1 (en) * 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0807065D0 (en) * 2008-04-18 2008-05-21 Univ Leeds Novel scaffolds
GB201805963D0 (en) * 2018-04-11 2018-05-23 Avacta Life Sciences Ltd PD-L1 Binding Affirmers and Uses Related Thereto
WO2019236567A2 (en) * 2018-06-04 2019-12-12 Trustees Of Tufts College Tumor microenvironment-activated drug-binder conjugated, and uses related thereto
WO2021074683A1 (en) * 2019-10-16 2021-04-22 Avacta Life Sciences Limited Bispecific anti-pd-l1 and anti-fcrn polypeptides

Also Published As

Publication number Publication date
JP2023536584A (ja) 2023-08-28
TW202221030A (zh) 2022-06-01
BR112023001588A2 (pt) 2023-04-04
IL300243A (en) 2023-03-01
EP4188957A1 (en) 2023-06-07
KR20230070201A (ko) 2023-05-22
WO2022023540A1 (en) 2022-02-03
AU2021314982A1 (en) 2023-03-02
US20230272011A1 (en) 2023-08-31
CN116419926A (zh) 2023-07-11
CA3187453A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
MX2023001261A (es) Polipéptidos de unión a albúmina sérica.
CR20220396A (es) Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos
UA107329C2 (uk) Туберкульозний білок rv2386c, композиція, що його містить, та застосування
UA103032C2 (uk) Селективні антитіла проти гепсидину-25 та їх застосування
WO2005021592A3 (en) Enhancing the circulating half-life of interleukin-2 proteins
MX2007003907A (es) Agentes terapeuticos con toxicidad reducida.
ATE490969T1 (de) Modifizierte transferrin-fusionsproteine
DK1572748T3 (da) Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2
GB2431583A (en) Combination therapy using transferrin fusion proteins comprising GLP-1
AR064706A1 (es) Composiciones y metodos para aplicacion topica y suministro transdermico de toxinas de botulina estabilizadas con fragmentos de polipeptido derivados de hiv -tat
UA107180C2 (uk) Туберкульозний білок rv1753c, композиція, що його містить, та застосування
BRPI0518793A2 (pt) mÉtodos para tratar, controlar ou prevenir uma doenÇa ou distérbio de imunodeficiÊncia, e para melhorar a resposta imune a um imunogene, e, composiÇço farmacÊutica
TW200602078A (en) Uses of anti-CTLA-4 antibodies
ITTO20050443A1 (it) Procedimento per la brasatura di parti di materiale composito sigillate con un composto a base di silicio.
HK1074670A1 (en) Sets of digital antibodies directed against short epitopes, and methods using same
MX2023004595A (es) Proteinas de fusion interleucina-2-fc y metodos de uso.
WO2014150600A8 (en) Modified toxins
MX2022009302A (es) Compuestos de unión a il-7r¿.
MX2022009390A (es) Compuestos de unión a il-7r¿¿c.
EA201100072A1 (ru) Новые композиции и способы
MX2021008207A (es) Proteínas de fusión multifuncionales y usos de las mismas.
WO2022051591A3 (en) Nectin-4 antibodies and uses thereof
MX2022009150A (es) Anticuerpos multiespecificos, composiciones que los comprenden, y vectores y usos de los mismos.
AU2002354806A1 (en) Parathyroid hormone antibodies and related methods
HK1076055A1 (en) Covalent conjugates between artemisinin-related endoperoxides and iron- carrying proteins and methods of use